Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

Group 1 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver with hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 2 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver without hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients. Group 3 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease with hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 4 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease without hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. No systemic HCC treatment in the previous 6 months. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients.